LA JOLLA, Calif.—The 2025 Advanced Lateral Flow Conference (ALFC), the premier global event for rapid diagnostics, today announced details of a high-profile session at the event. The session, Executive’s Corner: Running Diagnostics Companies in the Age of Complexity, will take place October 14 at 1 p.m. at the Hilton La Jolla Torrey Pines.
Moderated by James Zanewicz, JD, LLM, RTTP, CEO, Connect and EVP, Medicine and Research, Makyr, the panel will feature:
- Charlie Mamrak, CEO, DCN Dx
- Thomas Plotts, CFO / COO, Gravidas Diagnostics, Inc.
- Tony Serafini-Lamanna, President, Diagnostics, Meridian Bioscience
- Tomás Toribio, Managing Director, OPERON, S.A.
- Eirini Rapti, Co-founder and CEO, inne
This candid discussion will examine the realities of leading diagnostics companies today, from navigating capital and regulatory pressures to scaling teams, technology, and trust in a rapidly shifting market.
“Our industry is at an inflection point,” said James Zanewicz, session moderator. “Leaders are making difficult choices daily, balancing scientific progress with business realities. This panel is designed to pull back the curtain and give attendees real-world insight into what it takes to succeed in diagnostics right now.”
“We created this session because there has never been a more important time for diagnostics executives to share openly with each other,” said Charlie Mamrak, DCN Dx CEO. “We’re facing headwinds in capital markets, supply chains, and regulatory frameworks. This panel will be a space to address those challenges, consider what’s ahead in the next year, and engage directly with the audience on the questions that matter most.”
The 2025 ALFC will be held October 14–15 at the Hilton La Jolla Torrey Pines in La Jolla, California.
For more information and to register, visit alfc2025.com
About the Advanced Lateral Flow Conference
The Advanced Lateral Flow Conference (ALFC), presented by DCN Dx, is the leading global event for lateral flow diagnostic developers, manufacturers, and those driving their commercial success. This annual conference delivers cutting-edge insights through expert-led sessions and provides a platform for researchers and developers to exchange ideas and innovations. Attendees gain practical insights to advance their businesses, deepen their knowledge of rapid diagnostics, and connect with leading minds shaping the future of point-of-care testing.
The ALFC 2025 theme, Catalyzing Growth: Tech Advancements, Funding, and Regulatory Roadmaps in LFA, focuses on the three pillars driving real-world progress in diagnostics: capital, innovation, and regulatory clarity. From shifting FDA expectations to sustainable funding models and manufacturability challenges, the content will tackle the strategic decisions that shape successful lateral flow products.
Attendees include product managers, business development leads, investors, regulatory professionals, scientists, supply chain reps, and service providers from across the diagnostics ecosystem. These are the people responsible for turning ideas into impact, and ALFC is where they come to learn, connect, and get things done.
To learn more about ALFC, visit alfc2025.com.
About DCN Dx
DCN Dx, based in Carlsbad, California, specializes in lateral flow diagnostics development and manufacturing, and IVD regulatory consulting and clinical research. DCN Dx’s multidisciplinary CDMO specializes in creating tailored assay systems, consumables, and instruments for point-of-use applications, with a particular expertise in lateral flow assays. Their clinical research services group specializes in the planning, execution, and oversight of IVD clinical trials, inclusive of clinical operations, data management, and biostatistics, and regulatory services.
DCN Dx’s personalized approach to IVD product development and clinical trials has supported hundreds of programs and clients. They can oversee every stage from concept to assay development and platform integration, through clinical trials to manufacturing or only handle the aspects you request. In addition to lateral flow assays, DCN Dx’s clinical research expertise extends to any in vitro diagnostic, all with a focus on innovation, usability, and performance.
With a commitment to quality, customer satisfaction, and industry-leading expertise, DCN Dx is setting the benchmark for excellence in IVD services. To learn more about how we can support your diagnostic needs, visit dcndx.com.
